FeesSafety
Pluang+

Holy Crap Foods to debut new protein products at CHFA NOW Toronto trade show in Sept 2026

Company Fundamentals
15 Sep 2026
Newsfile Corp
View Source
Bullish
Holy Crap Foods to debut new protein products at CHFA NOW Toronto trade show in Sept 2026

Restart Life Sciences' subsidiary Holy Crap Foods will showcase its new protein product line alongside existing organic, plant-based foods at the CHFA NOW Toronto trade show on September 26-27, 2026. This marks Holy Crap's expansion into the protein and functional nutrition market, aiming to attract more health-conscious consumers beyond its core cereals and oatmeals. The event will also feature an interactive AI Photo Booth experience to engage attendees and boost brand visibility. This move supports the company's broader retail growth strategy in North America.

Holy Crap Foods' new protein product launch is presented here with a snapshot of the Consumer Staples sector on Pluang as of Sep 15, 2026 16:51 WIB. Of 46 priced US stocks in the sector, 14 rose and 27 fell. Among notable movers, CROX was priced at USD 112.20 with a 0.64% increase, contrasting with DNUT at USD 3.19 which declined by 0.47%, while HLF stood at USD 12.11 with a 0.46% rise.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
48 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App